with partial-onset seizures (POS) in the USA [2] , and as adjunctive therapy in adults (!16 years) with POS in the EU [3] and other countries. The efficacy and safety of adjunctive lacosamide have been demonstrated in three randomised placebo-controlled trials that recruited patients with uncontrolled POS [4] [5] [6] . Most patients (84.4%) were taking multiple (two or three) concomitant AEDs, with a lifetime use (started but previously discontinued) of >4 AEDs by 77.4% patients, and >7 AEDs by 45.2% patients [7] .
Since the chance of seizure freedom declines significantly with subsequent AED regimens [8] , it is of interest to assess the response to adjunctive lacosamide when used earlier in treatment than in the pivotal studies, such as first add-on therapy. In this study, we sought to evaluate the efficacy and safety of lacosamide in two populations of adults with POS using an evaluation schedule similar to the registration trials. The 'first add-on' cohort of patients received lacosamide as their first adjunctive treatment after a first monotherapy, while the 'later add-on' cohort had previously been treated with at least two prior AED treatment regimens before adding lacosamide.
Methods
This was a prospective open-label, non-randomised, Phase IIIb/IV study (SP0954; NCT00955357), conducted between August 2009 and August 2013 at sites in Austria, Bulgaria, Czech Republic, Denmark, Finland, France, Greece, Italy, Romania, Russia, Spain, Turkey, Mexico and the USA, according to ICH-GCP [9] , the Declaration of Helsinki, and local laws of the countries involved. All patients provided written informed consent and the study was approved by an Ethics Committee or Institutional Review Board for each site.
Patients

Overall study population
The study enrolled male or female adults (aged !18 years in Mexico or Bulgaria, !17 years in the USA and !16 years in all other countries). Patient enrolment criteria required a diagnosis of epilepsy with simple partial seizures (SPS) and a motor component or complex partial seizures (CPS) with or without secondarily generalised seizures (sGS). The maximum permitted seizure frequency (motor and non-motor) during the 12 weeks prior to screening (Historical Baseline) was 40 POS per 28 days. Patients were required to be lacosamide-naïve and maintained on a stable AED regimen for at least 7 days prior to screening, with or without concurrent stable vagus nerve stimulation.
Patients were excluded if they had a seizure disorder characterised primarily by POS without motor signs, a history of primary generalised seizures or status epilepticus, uncountable seizures due to clustering or possible non-epileptic seizures/events. Patients were also excluded if they had any medical or psychiatric condition that might compromise their health, ability to participate in the trial or could interfere with lacosamide pharmacokinetics.
First add-on cohort
Patients included in the first add-on cohort were taking an appropriate first monotherapy, defined as a single AED taken for at least 28 days prior to screening, and had no history of AED polytherapy. Prior short-term intermittent rescue therapy was accepted. At screening, patients had 24 months since epilepsy diagnosis, and experienced !3 POS (SPS with motor signs, CPS or sGS) at any time during the 12-week Historical Baseline.
Later add-on cohort
The later add-on cohort included patients with more treatmentrefractory epilepsy, who were taking 1-3 AEDs, had received !2 prior AED treatment regimens (concurrently or sequentially), and had been diagnosed with epilepsy at least 5 years before screening. They had a POS frequency (SPS with motor signs, CPS or sGS) of !1 per 28 days during the 12-week Historical Baseline.
Treatment
The study design is shown in Supplemental Figure 1 . Eligible patients received open-label twice-daily oral treatment with lacosamide tablets. Scheduled clinic visits were at screening (1 week before treatment initiation), and at Weeks 0 (treatment initiation), 5, 6 (end of Titration Phase), 12, 18, 24 and 30 (End of Maintenance Phase), followed by a Taper/Safety Follow-Up Phase of up to 3 weeks.
During the 6-week Titration Phase, lacosamide was initiated at 100 mg/day (50 mg bid) and then increased by 100 mg/day/week for 4 weeks to a maximum of 400 mg/day (200 mg bid). Changes to concomitant AED treatment were not allowed until the end of Weeks 4 and 5, when existing doses could be adjusted (no new AED additions were permitted). A reduction in the lacosamide dosage to 300 mg/day was permitted (if required) at the end of Week 5.
One increase (to a maximum of 400 mg/day) or decrease (to a minimum of 300 mg/day) of the lacosamide dose was allowed at the end of Week 12 of the Maintenance Phase. No other change to the lacosamide dose was permitted thereafter. Changes to concomitant AEDs were not allowed at any time during the Maintenance Phase. Patients who completed the 24-week Maintenance Phase and chose not to continue receiving commercial lacosamide were gradually tapered off.
Patient analysis sets
The Safety Set (SS) included all patients who received at least one dose of lacosamide during the study. The full analysis set (FAS) included patients of the SS who had at least one post-Baseline seizure assessment. The Completer Set (CS) was defined as patients of the FAS who completed the first 12 weeks of the Maintenance Phase. Patients in the FAS who completed the 24-week Maintenance Phase were considered 24-week completers.
Outcome measures and statistical analysis
The primary efficacy outcome was the proportion of patients among the CS who achieved seizure freedom, i.e. reported no seizures, with no missing seizure data, during the first 12 weeks of the Maintenance Phase.
The proportion of patients who achieved seizure freedom throughout the 24-week Maintenance Phase was also analysed among 24-week completers. The percentage change in POS frequency per 28 days was evaluated from Baseline to the first 12 weeks of maintenance therapy among the CS, and at the end of the 24-week Maintenance Phase in the FAS, using the last observation carried forward (LOCF) method. Responder rates (proportions of patients with !50% or !75% decrease in POS frequency per 28 days from Baseline) were analysed after 12 weeks of maintenance therapy among the CS, and at the end of the 24-week Maintenance Phase in the FAS (LOCF).
Other efficacy measures analysed among the FAS population included the change in clinical status measured by the Clinical Global Impression of Change (CGIC) and the Patient's Global Impression of Change (PGIC) at the end of the Maintenance Phase/ Early Discontinuation. The Quality of Life (QOL) Inventory in Epilepsy-31-P (QOLIE-31-P) was completed by all capable patients to assess the effects of treatment on activities of daily living and overall health-related QOL across seven domains. The QOLIE-31-P is an adaptation of the QOLIE-31, grouped into seven subscales and a weighted total score with additional items of 'distress' and 'prioritisation' for each subscale [10] . Total and subscale scores range from 0 to 100, where higher scores indicate better QOL. Mean change in QOLIE-31-P score from Baseline to the end of the 24-week Maintenance Phase was analysed for 24-week completers and the FAS using LOCF. Descriptive statistics were Cohen's deffect size and p-values from paired t-tests. The proportion of patients achieving clinically meaningful improvements in QOL was estimated using previously defined thresholds [11] .
Safety was assessed for the SS based on treatment-emergent adverse events (TEAEs), patient withdrawals due to TEAEs, vital signs and laboratory evaluations.
Seizure freedom and safety data were also analysed for subgroups of patients with or without concomitant use of one or more of the following traditional sodium channel-blocking (SCB) AEDs: carbamazepine, lamotrigine, oxcarbazepine, phenytoin, rufinamide and eslicarbazepine.
A descriptive analysis was used for all variables. Enrolment of 656 patients was planned and progressed more quickly for the later add-on cohort than the first add-on cohort. When recruitment closed, the target patient number was not reached for the first addon cohort. Direct comparison between the first add-on and later add-on cohorts was neither planned, nor conducted, in this study.
Results
Of 461 patients enrolled in the study, 456 received at least one dose of lacosamide (SS), and 444 patients completed at least one post-baseline seizure assessment (FAS) (Fig. 1) . Five patients were excluded from all analysis sets due to significant conduct deficiencies at one site. History of epilepsy and lifetime/concomitant AED use reflected the enrolment criteria for each cohort (Table 1) . Concomitant SCB AEDs were taken by more patients in the later addon cohort (74.2%) than in the first add-on cohort (54.2%).
First add-on cohort
Of 96 treated patients (SS), 80 (83.3%) completed the Titration Phase, 72 (75.0%) completed the first 12 weeks of the Maintenance Phase (CS), and 68 (70.8%) completed the 24-week Maintenance Phase (24-week completers) (Fig. 1) .
Efficacy
Seizure freedom was achieved by 37.5% of patients in the first add-on cohort who completed the first 12 weeks of the Maintenance Phase and by 26.5% of 24-week completers ( Fig. 2A) . POS frequency per 28 days decreased from Baseline to Week 12 of the Maintenance Phase (median percent change À91.3% [range À100% to 343.9%], CS) and during the 24-week Maintenance Phase (median change À90.5% [À100% to 1720%], FAS). This was associated with !50% responder rates of 76.4% after 12 weeks of maintenance therapy and 70.3% after 24 weeks (Fig. 2B ). Among the subgroup of patients taking SCB AEDs and completing 12 weeks of maintenance therapy, 10/36 (27.8%) achieved seizure freedom, while 4/33 (12.1%) patients remained seizure-free after 24 weeks. Corresponding seizure freedom rates among patients taking non-SCB AEDs were 17/36 (47.2%) and 14/ 35 (40.0%).
At the end of treatment, clinicians rated patients' clinical status as improved for 73/86 (84.9%) patients in the first add-on cohort (FAS), comprising 20 patients (23.3%) considered very much improved, 41 (47.7%) much improved and 12 (14.0%) minimally improved (Supplemental Figure 2 ). Few patients were considered to have had no change (8/86, 9.3%) or worsened (5/86, 5.8%). A similar trend was seen for the patient-reported PGIC, with 66/83 (79.5%) patients indicating an improvement, comprising 21 (25.3%) very much improved, 36 (43.4%) much improved and 9 (10.8%) minimally improved; 9/83 patients (10.8%) had no change, and 8/83 (9.6%) worsened.
Quality of life
Among 24-week completers in the first add-on cohort there was an improvement in overall QOL with a mean AE SD change from Baseline in QOLIE-31-P total score of 7.1 AE 16.00 and an associated Cohen's d-effect size of 0.44 (Table 2) , suggesting a moderate improvement. Using pre-defined thresholds [11] , 49.2% (32/65) of completers showed a clinically meaningful improvement in the QOLIE-31-P total score (Supplemental Table 1 ). Improvements were observed across all subscale scores, with the greatest for seizure worry (+13.3 AE 26.44 points from Baseline). Across all subscales, 40.0-53.8% of patients showed clinically meaningful improvements. Similar results were noted for the FAS, with the exception of medication effects (À1.1 AE 33.23 points from Baseline); 39.8% of patients reported a clinically meaningful improvement.
Safety and tolerability
During the Treatment Phase, the mean duration of lacosamide exposure in the first add-on cohort was 168.4 days, and the median mean exposure was 363.6 mg/day (Table 3) .
TEAEs were reported for 69.8% of patients in the first add-on cohort, most frequently dizziness, headache, vertigo and nausea (Table 3) . Most TEAEs were mild or moderate in intensity; 10 patients (10.4%) experienced a severe TEAE. The overall incidence of new-onset TEAEs was highest during the Titration Phase (Table 4) .
TEAEs were reported by 71.2% of patients taking SCB AEDs (37/ 52) and 68.2% (30/44) of those taking non-SCB AEDs. The most commonly reported TEAEs among SCB AED users were dizziness (20/52, 38.5%), headache (7/52, 13.5%), vertigo (6/52, 11.5%), nausea, influenza (each 5/52, 9.6%), somnolence, anxiety and diplopia (each 4/52, 7.7%). The most commonly reported TEAEs among patients taking non-SCB AEDs were dizziness (10/44, 22.7%), headache (6/44, 13.6%), vertigo, nausea, diplopia, depression, irritability and nasopharyngitis (each 3/44, 6.8%).
TEAEs led to study discontinuation of 12 (12.5%) patients in the first add-on cohort ( Table 3 ). The most common TEAE leading to discontinuation was dizziness, onset of which occurred during Titration for all patients. Eleven patients discontinued due to TEAEs with onset during the Titration Phase, 9 of who discontinued during the Titration Phase. Eight (8.3%) patients experienced serious adverse events (SAEs) and one patient died during the study; following a subdural haematoma caused by a fall, not considered by the investigator to be related to treatment.
No effect of lacosamide as a first add-on was observed for neurological and vital signs, laboratory results or ECG. 
Later add-on cohort
Of 360 treated patients (SS), 294 (81.7%) completed the Titration Phase, 261 (72.5%) completed the first 12 weeks of the Maintenance Phase (CS) and 249 (69.2%) completed the 24-week Maintenance Phase (24-week completers) (Fig. 1) .
Efficacy
Seizure freedom was achieved by 39 of 261 (14.9%) patients in the later add-on cohort who completed the first 12 weeks of the Maintenance Phase, the majority of whom remained seizure-free (11.6%) for 24 weeks of maintenance therapy ( Fig. 2A) 
Quality of life
Among 24-week completers in the later add-on cohort there was an improvement in overall QOL with a mean AE SD change from Baseline in QOLIE-31-P total score of +4.8 AE 14.74 points and an associated Cohen's d-effect size of 0.33 (Table 2 ). Using pre-defined thresholds [11] , 43.1% of completers (103/239) showed clinically meaningful improvements in the QOLIE-31-P total score (Supplemental Table 1 ). Improvements were observed across all subscales with the greatest improvement for social function (+8.1 AE 23.74 points from Baseline). Across all subscales, 36.0-53.7% of patients showed clinically meaningful improvements. Similar results were noted for the FAS, with the exception of medication effects (À2.4 AE 30.28 points from Baseline); 37.5% of patients reported a clinically meaningful improvement.
Safety and tolerability
Mean duration of lacosamide exposure during the Treatment Phase in the later add-on cohort was 165.2 days, and median mean exposure was 373.9 mg/day (Table 3) .
TEAEs were reported for 73.6% of patients in the later add-on cohort, most frequently dizziness, somnolence and headache (Table 3) . Most TEAEs were mild or moderate in intensity; 36 Table 2 Change from baseline in QOLIE-31-P scores and subscales for patients adding lacosamide as a first add-on or later add-on treatment (24-week Maintenance Phase completers).
First add-on
Later add-on patients (10.0%) experienced a severe TEAE. The overall incidence of new-onset TEAEs was highest in the Titration Phase (Table 4) . TEAEs were reported by 76.4% of patients taking SCB AEDs (204/ 267) and 65.6% (61/93) of those taking non-SCB AEDs. The most commonly reported TEAEs among SCB AED users were dizziness (103/267, 38.6%), somnolence (36/267, 13.5%), headache (33/267, 12.4%), vision blurred (21/267, 7.9%), vertigo (20/267, 7.5%), nausea (18/267, 6.7%) and diplopia (16/267, 6.0%). The most commonly reported TEAEs among users of non-SCB AEDs were dizziness, somnolence (each 18/93, 19.4%), tremor (9/93, 9.7%), headache (8/ 93, 8.6%), nausea, irritability and urinary tract infection (each 6/93, 6.5%).
TEAEs led to study discontinuation of 69 (19.2%) patients in the later add-on cohort (Table 3) : 46 (12.8%) patients discontinued due to TEAEs during the Titration Phase, 20 (5.6%) discontinued during the first 12 weeks of the Maintenance Phase and three (0.8%) during the last 12 weeks of the Maintenance Phase. The most common TEAE leading to discontinuation was dizziness, which had an onset during Titration for 29/33 patients. Seventeen (4.7%) patients in the later add-on cohort experienced SAEs (Table 3 ). The incidence of TEAEs involving haematology and clinical chemistry values was low, including one serious TEAE of agranulocytosis, and two clinical chemistryrelated SAEs (hypochloraemia and hyponatraemia, both not considered treatment-related and occurred in the same patient). The event of agranulocytosis occurred in a 25-year-old male patient who had been on study medication for 46 days and was taking 400 mg/day lacosamide adjunctive to lamotrigine and levetiracetam at the time of the event. The SAE was classified as related to lacosamide treatment, which was discontinued. The TEAE resolved in 7 days. There was one clinically significant ECG abnormality (a SAE of ST elevation, considered possibly related to study medication and leading to discontinuation of 100 mg/day lacosamide, taken adjunctive to carbamazepine and levetiracetam). No consistent or clinically relevant effect of lacosamide as a later add-on was observed for neurological and vital signs, or laboratory results.
Discussion
Lacosamide has been extensively evaluated in difficult-to-treat patients. The results of this study indicated that lacosamide is also efficacious as a first add-on treatment for uncontrolled POS.
The antiepileptic efficacy achieved with first add-on lacosamide supports previous studies of early lacosamide use, with 26.5% of patients remaining seizure-free over 24 weeks of maintenance therapy and 70% responding with !50% reductions in seizure frequency. Although a potential limitation of this study is the 6-month duration for evaluation of seizure freedom (in accordance with the ILAE consensus definition, 12 months is typically required among patients with treatment-refractory epilepsy [12] ), similar findings were observed in the non-interventional VITOBA study, where lacosamide initiated as an add-on to monotherapy for POS led to seizure freedom during the final 3 months of the 6-month study in 45.5% of 494 patients taking in-label doses, and 72.5% of patients showed a !50% response [13] . In that study, of the 190 patients who received lacosamide after first monotherapy, 60.5% became seizure-free and 82.1% showed !50% response. Somewhat lower seizure freedom and !50% response rates were seen among the 304 patients who had received more than one previous AED [13] . Despite differences in the definition of seizure freedom, the retrospective, observational LACO-EXP study also reported that the proportion of !50% responders during lacosamide therapy progressively declined with increasing numbers of prior AEDs [14] . Prospective audits of lacosamide and other newer agents support these findings, showing seizure freedom was more commonly achieved in patients treated for uncontrolled POS when added as a first or second add-on [15] .
Interpretation of the findings from this study is limited by the open-label, non-randomised design, and the failure to enrol the target number of patients in the first add-on cohort. This resulted in an imbalance in patient numbers between the two cohorts. Direct comparison between first-add-on and later add-on cohort was neither planned nor possible.
In the current study, 11.6% of patients who added lacosamide later in their therapy achieved seizure freedom for 24 weeks after initiating lacosamide treatment. This was somewhat higher than the 3.3% of patients in registration trials who took 400 mg/day lacosamide adjunctive to 1-3 AEDs (83.3% 2-3 AEDs) for [16] [17] [18] weeks [4] [5] [6] . A !50% reduction in seizure frequency was reported by 50.4% of patients in the current study, also higher than that observed for patients who took 400 mg/day lacosamide in the registration trials (39.7%) [7] . Although the duration of epilepsy was comparable for patients in this study and those in the registration trials, later add-on patients in the current study reported fewer lifetime AEDs (32.8% vs. 77.4% had used at least 4 AEDs) and had a lower median Baseline seizure frequency (3.7 vs. 11.5/28 days). Nonetheless, it should be noted that use of a retrospective Baseline in this study may have underestimated the Baseline seizure frequency compared with the prospective Baselines used in the registration trials. Responder and seizure freedom rates comparable to those observed here have previously been reported with lacosamide therapy in treatment-refractory patients. In the LACO-EXP study, 14.9% of patients taking lacosamide at a median dosage of 400 mg/day were seizure-free for the 12-month study, with 57.1% considered to be !50% responders [14] . Poorer efficacy outcomes are generally expected from more refractory epilepsy populations [8, 14, 16, 17] , however, findings from this study support a conclusion that improvements in seizure frequency may be obtained with lacosamide treatment taken as a first or later add-on therapy.
The antiepileptic efficacy of lacosamide was accompanied by improvements in QOL and in patient-and physician-rated overall clinical health status. In this study, mean changes in QOLIE-31-P from Baseline and Cohen's d-effect sizes showed improvements in overall QOL both in study completers and the FAS, being numerically higher in the first add-on group. Across all QOLIE-31-P subscales, clinically relevant improvements were observed in 40.0-53.8% of 24-week completers in the first add-on cohort, when assessed using pre-defined thresholds [11] . An improvement in medication effects was seen in 43.1% of completers, which, alongside the 12.5% of patients discontinuing the study due to AEs, supports the conclusion that 300-400 mg/day lacosamide was well tolerated in this patient cohort. The greatest improvement was observed for seizure worry, most likely reflecting the reduced seizure frequency achieved in these patients. Among 24-week completers in the later add-on cohort, clinically relevant improvements were observed for in 36.0-53.7% of patients across all QOLIE-31-P subscales. In the later add-on FAS population, QOLIE-31-P scores were consistent with QOL improvements seen among refractory patients in a Phase IIb trial (at 400 mg/day lacosamide, assessed using the QOLIE-31 scale [4] and among responders to lacosamide therapy in a pooled analysis [18] . These findings suggest a positive effect on QOL with adjunctive lacosamide therapy added early or later into the treatment paradigm.
Post hoc analyses of controlled studies in adults with focal epilepsy have shown the pharmacokinetic profile of lacosamide to be unaffected by age (16-71 years) or gender [19] , with pharmacokinetic studies currently underway in paediatric patients (including SP0847 [NCT00938431], SP0969 [NCT01921205] and SP1047). However, evaluation of the safety and effectiveness of lacosamide therapy among patient sub-groups in a setting which more closely represents real-life clinical practice is of additional interest, in particular, findings among patients adding lacosamide to traditional SCB AEDs and in those taking AEDs with a different mode of action. Some studies have reported similar seizure control among these patient subgroups [13, 20] . However, exploratory analyses undertaken in the current study are consistent with other reports [14, 17, 21, 22] indicating that seizure freedom was more achievable in patients adding lacosamide to treatment regimens which do not include traditional SCB AEDs. This was particularly true in patients who added lacosamide to a first AED. Although lacosamide is not a traditional SCB AED, these findings may be attributed to the ability of lacosamide to selectively facilitate slow inactivation of sodium channels [23] . However, due to the uncontrolled nature of this study and the small numbers of patients in each subgroup, caution should be applied when interpreting such observations.
Alongside positive efficacy findings and observed in improvements quality of life, the safety profile for lacosamide 300-400 mg/ day when initiated as a first or later add-on therapy was consistent with the known profile for adjunctive lacosamide [4] [5] [6] , with tolerability improving over the study duration. Pharmacokinetic assessments have shown lacosamide to have limited interactions with a range of other AEDs, and consistent with previous studies, the nature of the most commonly reported TEAEs were similar in patients adding lacosamide to a regimen with or without a SCB AED [2,7,21].
Conclusion
The results of this study support the use of lacosamide as an efficacious and well-tolerated agent for the early treatment of uncontrolled POS. They highlight the potential for a substantial number of patients to achieve seizure freedom and marked reductions in seizure frequency when treated with lacosamide as a first add-on therapy at doses of 300-400 mg/day.
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